RxDoctor Payments Data

Lyndon Mansfield

Allergy & Immunology · El Paso, TXNPI 1508936170

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,077 of the $19,947 with a category attached, or 90.6%. Boehringer Ingelheim accounts for 79.0% of it on its own, with 2 other manufacturers making up the rest.

$19,947in general payments, 2019–2025

Across 14 payments — averaging $1424.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$16K
  • Boehringer Ingelheim International GmbH$2K
  • Novartis$2K
$2,368,654in research payments, 2019–2025

Across 210 payments — averaging $11,279 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$631K
  • Amphastar Pharmaceuticals, Inc.$590K
  • Hikma Pharmaceuticals USA$352K
  • Novartis$320K
  • Cipla USA Inc.$318K
  • AstraZeneca$107K
  • plus $50K from 4 others

What the payments were for

  • Speaking & faculty fees$18,07791%
  • Travel & lodging$1,4257%
  • Food & beverage$4462%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,947 in reported general payments places this provider in the 80th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Other allergy & immunology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →